{"product_id":"neurenpharma-swot-analysis","title":"Neuren Pharmaceuticals SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNeuren Pharmaceuticals shows promising neurodevelopmental drug candidates and strong orphan-drug positioning, but faces funding constraints and regulatory risk that could impact commercialization timelines; competitive biologics and trial dependency add execution challenges. Discover the full SWOT to see revenue scenarios, risk mitigants, and strategic options—purchase the complete, editable report (Word + Excel) to inform investment or partnership decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Commercial Success with DAYBUE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren has moved to commercial stage with DAYBUE, the first FDA-approved Rett syndrome treatment, and US net sales grew to about US$400 million in 2025, showing consistent year-over-year uptake.\u003c\/p\u003e\n\u003cp\u003eThis performance creates a high-margin royalty stream and validates Neuren’s ability to convert orphan-drug R\u0026amp;D into global commercial success, de-risking future launches and partnering deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Position and Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren entered 2026 with about A$300 million in cash and short-term investments, providing strong liquidity to fund operations.\u003c\/p\u003e\n\u003cp\u003eQuarterly royalties from Acadia Pharmaceuticals plus milestone receipts cover R\u0026amp;D spend, avoiding further equity dilution.\u003c\/p\u003e\n\u003cp\u003eManagement launched a 5% share buyback in early 2026, signaling confidence in the company’s cash-generative model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Value Rare Disease Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuren is advancing NNZ-2591 in Phelan-McDermid, Pitt-Hopkins and Angelman syndromes, addressing high unmet needs where no approved therapies exist; the Koala Phase 3 for Phelan-McDermid is recruiting as of Jan 2026 and targets an estimated 20,000 global patients. \u003c\/p\u003e\n\u003cp\u003ePipeline diversity beyond trofinetide reduces single-product commercial risk and could expand peak revenue potential—analyst models in 2025 projected combined rare-disease peak sales of $400–600M if trials succeed. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Global Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuren leverages an exclusive worldwide license with Acadia Pharmaceuticals, which funds commercialization and regulatory filings in major markets, letting Neuren keep a lean corporate cost base (R\u0026amp;D-focused; 2024 cash burn cut to ~A$8m\/month). \u003c\/p\u003e\n\u003cp\u003eAcadia provides established US sales channels and customer-facing teams, enabling faster market access; trofinetide approved in US (Mar 2023) and Canada (2024), with EU and Japan reviews ongoing as of Dec 2025. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicense: exclusive worldwide with Acadia\u003c\/li\u003e\n\u003cli\u003eCost: Acadia funds commercialization\u003c\/li\u003e\n\u003cli\u003eLean ops: Neuren conserves capital (~A$8m\/month burn in 2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory: US approval Mar 2023; Canada 2024; EU\/Japan reviews active Dec 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Orphan Drug Protections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuren’s candidates hold FDA and EMA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, giving up to 7.5 years US and 10–12 years EU exclusivity, sharply raising competitor entry costs.\u003c\/p\u003e\n\u003cp\u003ePriority Review Voucher (PRV) eligibility could yield a non-dilutive windfall; recent PRV sales fetched $80–200M (2018–2021 range), offering material funding on approval.\u003c\/p\u003e\n\u003cp\u003eRegulatory shields shorten development risk, improve partnering leverage, and enhance NPV for investors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS exclusivity: up to 7.5 years\u003c\/li\u003e\n\u003cli\u003eEU exclusivity: 10–12 years\u003c\/li\u003e\n\u003cli\u003ePRV market value: ~$80–200M historical range\u003c\/li\u003e\n\u003cli\u003eDesignations: Orphan, Fast Track, Rare Pediatric Disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuren: DAYBUE $400M (2025), A$300M cash, Phase‑3 NNZ‑2591 \u0026amp; orphan exclusivities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuren reached commercial stage with DAYBUE (US sales ~US$400M in 2025), A$300M cash at start-2026, recurring royalties and milestones funding R\u0026amp;D, exclusive Acadia license reducing operating cost (~A$8m\/month 2024), NNZ-2591 Phase 3 recruiting (Koala for Phelan-McDermid, Jan 2026), orphan\/PRV exclusivities enhancing valuation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 US sales\u003c\/td\u003e\n\u003ctd\u003eUS$400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eA$300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBurn\u003c\/td\u003e\n\u003ctd\u003eA$8M\/mo (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Neuren Pharmaceuticals, highlighting its clinical-stage neuroscience focus and proprietary peptide assets as strengths, limited commercial revenue and funding reliance as weaknesses, opportunities from orphan-disease approvals and partnerships, and threats from regulatory hurdles, competitive biologics, and market adoption challenges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Neuren Pharmaceuticals to quickly align strategy around its clinical pipeline strengths, commercialization risks, and partnership opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Dependency on a Single Partner\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren’s 2025 cash flow depends heavily on Acadia Pharmaceuticals’ commercial execution for trofinetide; Acadia reported net product revenue of $420m in 2024, so any sales slowdown would hit Neuren’s royalty stream hard.\u003c\/p\u003e\n\u003cp\u003eOperational setbacks, marketing shifts, or Acadia restructuring could cut royalty receipts that funded Neuren’s FY2024 R\u0026amp;D and G\u0026amp;A (A$23m cash at 31 Dec 2024), exposing liquidity risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Neurodevelopmental Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuren focuses exclusively on pediatric neurology and neurodevelopmental disorders, a high-risk niche where global clinical success rates for CNS drugs are ~8.2% (Biotech 2023).\u003c\/p\u003e\n\u003cp\u003eThis concentration raises vulnerability: a regulatory change or negative Phase 3 readout could wipe pipeline value—market cap was NZD 240m on 30 Sep 2025, so downside is material.\u003c\/p\u003e\n\u003cp\u003eIf the lead mechanism fails, the company lacks diversification to offset lost R\u0026amp;D, hitting revenues and investor confidence hard.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Direct Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy outsourcing sales and marketing, Neuren Pharmaceuticals misses margin capture—partner royalties often leave 30–50% of retail value to partners; Neuren reported NZD 7.2m revenue in FY2024, highlighting limited commercial upside.\u003c\/p\u003e\n\u003cp\u003eLacking in-house launch and distribution capabilities, Neuren would face multi-year, multi-million-dollar builds (estimated NZD 20–50m) to go direct, raising execution risk if a partner deal ends.\u003c\/p\u003e\n\u003cp\u003eThis dependence on third parties constrains strategic flexibility and vertical integration, limiting control over pricing, market access, and patient services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Small-Cap Biotech Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNeuren Pharmaceuticals faces small-cap biotech volatility: despite commercial progress, its NZX\/ASX-listed shares (market cap ~NZD 220m as of Dec 31, 2025) swing sharply on trial and regulatory news.\u003c\/p\u003e\n\u003cp\u003eRecent FDA written-only feedback in 2025 triggered \u0026gt;30% intraday moves, showing how timeline or delay fears can skew valuations and stress capital plans.\u003c\/p\u003e\n\u003cp\u003eThis volatility can hurt cash runway planning and erode investor confidence in broader market selloffs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket cap ~NZD 220m (12\/31\/2025)\u003c\/li\u003e\n\u003cli\u003eSingle-regulatory updates moved price \u0026gt;30% in 2025\u003c\/li\u003e\n\u003cli\u003eVolatility complicates fundraising and cash-runway\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Revenue Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs of end-2025, about 82% of Neuren Pharmaceuticals’ revenue came from the United States, leaving the company exposed to a single-market risk.\u003c\/p\u003e\n\u003cp\u003eDelays in EU or Japan reimbursement or regulatory approval—where launch timelines target 2026–2027—could stall projected revenue growth and pressure margins.\u003c\/p\u003e\n\u003cp\u003eHigh growth depends on penetrating varied healthcare systems with distinct pricing, reimbursement, and access rules; failure raises churn and valuation risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e82% revenue from US (2025)\u003c\/li\u003e\n\u003cli\u003eEU\/Japan launches targeted 2026–2027\u003c\/li\u003e\n\u003cli\u003eRegulatory\/reimbursement delays = stalled growth\u003c\/li\u003e\n\u003cli\u003eDiverse pricing\/access risks across markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh concentration \u0026amp; liquidity risk: 82% US revenue, A$23m cash, NZD220m market cap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration risk: 82% revenue from US (2025) and heavy reliance on Acadia’s trofinetide sales (Acadia net product revenue US$420m in 2024) creates liquidity exposure—Neuren had A$23m cash at 31‑Dec‑2024.\u003c\/p\u003e\n\u003cp\u003eSmall-cap volatility: market cap ~NZD220m (31‑Dec‑2025); single regulatory updates moved price \u0026gt;30% in 2025, complicating fundraising.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS revenue share (2025)\u003c\/td\u003e\n\u003ctd\u003e82%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcadia 2024 sales\u003c\/td\u003e\n\u003ctd\u003eUS$420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuren cash\u003c\/td\u003e\n\u003ctd\u003eA$23m (31‑Dec‑2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket cap\u003c\/td\u003e\n\u003ctd\u003e~NZD220m (31‑Dec‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNeuren Pharmaceuticals SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It outlines Neuren Pharmaceuticals' strengths, weaknesses, opportunities, and threats with concise, actionable insights tailored for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752562110841,"sku":"neurenpharma-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/neurenpharma-swot-analysis.png?v=1772242417","url":"https:\/\/growthsharematrix.com\/products\/neurenpharma-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}